The history of asthma
Last reviewed November 16, 2026. OwieClear editorial team. Waiting for clinician review. Not medical advice. Talk with your doctor about your own care.
The word is Greek and very old. What changed recently is not the recognition of asthma but the understanding of what it is: for most of medical history it was treated as a spasm of the airway, and the inflammation underneath was missed.
Two episodes in the twentieth century, both involving deaths caused by treatment, pushed the field toward the approach used now.
Related pages: Asthma
The bottom line
- Asthma has been described since antiquity.
- Inhaled corticosteroids transformed outcomes from the 1970s onwards.
- Reliever-only treatment was associated with excess deaths.
- Guidelines now treat asthma primarily as an inflammatory disease.
- Why asthma deaths still occur in countries with good access to treatment.
- Whether early treatment can alter the long-term course of the disease.
The story, step by step
What the evidence labels mean
Named and described
What happens
The word and the first descriptions come from Greek medicine.
What the research shows
- Asthma derives from a Greek word for panting or short breath, and appears in the Hippocratic writings around the fifth century BCE.
- Egyptian and Chinese texts describe remedies for breathing difficulty that are older still, including inhaled herbal preparations.
- Aretaeus of Cappadocia, in the second century CE, gave a clear description of episodic breathlessness relieved by rest.
- In the twelfth century Maimonides wrote a treatise on asthma for a patient, and included observations on climate, diet and sleep that read sensibly today.
- Throughout this period asthma was understood as an obstruction or a spasm, with no concept of inflammation.
Why it matters
Asthma was recognized as episodic and reversible very early, which is why treatment focused for so long on relieving the episode.
What's still uncertain
- Ancient descriptions of breathlessness do not map cleanly onto modern diagnostic categories.
Read more
- US National Library of Medicine: Hippocrates and the Hippocratic corpusGovernment
- NIH National Library of Medicine: History of MedicineGovernment
Next: 1698 to 1900
Observation sharpens
What happens
A long period of better description without better treatment.
What the research shows
- In 1698 John Floyer, who had asthma himself, published a treatise distinguishing it from other causes of breathlessness and noting triggers and family occurrence.
- In 1860 Henry Hyde Salter published a detailed account describing the night-time pattern, the role of triggers, and relief from strong coffee, which contains a compound related to theophylline.
- Salter also observed the airway narrowing and recognized that something more than spasm was involved.
- William Osler, around 1900, described the thickened airway wall and mucus plugging seen after death, which was a direct observation of inflammation.
- Treatments of the era included smoking preparations of stramonium, which contains an anticholinergic drug, and so did have genuine bronchodilator effect.
Why it matters
The pathology of inflammation was visible by 1900. Acting on it took most of another century.
What's still uncertain
- Post-mortem findings came from people who died of asthma, which may not represent the usual disease.
Read more
Next: 1900 to 1960
Relievers arrive
What happens
Effective bronchodilators transformed the experience of an attack, and shaped a treatment philosophy that later proved harmful.
What the research shows
- Adrenaline injection came into use for acute asthma in the early 1900s and was genuinely life-saving.
- Ephedrine and theophylline followed as oral treatments.
- The pressurized metered-dose inhaler was introduced in 1956, reportedly after a teenager with asthma asked her father, a pharmaceutical executive, why her medicine could not come in a spray can like hairspray.
- Isoprenaline inhalers made relief quick and portable, and treatment became centred almost entirely on relieving symptoms.
- Asthma was widely regarded during this period as a psychosomatic condition, a view that caused real harm and took decades to dislodge.
Why it matters
The era established the inhaler as the format for asthma treatment, and established the mistaken idea that relieving symptoms was the whole job.
What's still uncertain
- How much of the psychosomatic framing affected care is hard to quantify in retrospect.
Read more
- NIH National Library of Medicine: History of MedicineGovernment
- NHLBI: AsthmaGovernment
Next: The epidemics
Deaths caused by treatment
What happens
Two waves of excess asthma deaths changed the field, and both involved relievers.
What the research shows
- In the 1960s an epidemic of asthma deaths in the UK, New Zealand and several other countries was linked to high-dose isoprenaline inhalers.
- In the 1970s and 1980s New Zealand experienced a second epidemic, associated with fenoterol, a potent reliever.
- Investigation suggested the mechanism was not simple drug toxicity but over-reliance on relief: effective symptom relief allowed people to continue through worsening inflammation until the attack became unsurvivable.
- Withdrawal of the implicated inhalers coincided with falling death rates.
- This history is the reason current guidelines treat frequent reliever use as a danger signal rather than as adequate treatment.
Why it matters
The lesson is specific and still relevant: feeling better after a reliever does not mean the asthma is under control.
What's still uncertain
- Attributing an epidemic to a single drug remains debated, and other factors were likely involved.
Read more
- Global Initiative for Asthma (GINA): ReportsNonprofit
- NHLBI: AsthmaGovernment
Next: 1972 onwards
Treating the inflammation
What happens
Inhaled corticosteroids changed outcomes more than any other development.
What the research shows
- Beclomethasone, the first widely used inhaled corticosteroid, became available in 1972 and delivered anti-inflammatory treatment to the airway at doses that largely avoided the harms of oral steroids.
- Salbutamol, more selective and safer than isoprenaline, became the standard reliever.
- Long-acting bronchodilators arrived in the 1990s, with early safety concerns when used without an inhaled steroid, leading to the rule that they are never used alone in asthma.
- Leukotriene receptor antagonists followed, and in 2020 the FDA added a boxed warning to montelukast about serious mental health side effects.
- The first GINA global strategy appeared in the 1990s. Biologic antibody treatments arrived from 2003 onwards, and in 2019 GINA withdrew its recommendation for reliever-only treatment at any severity.
Why it matters
The modern standard is anti-inflammatory treatment taken whenever a reliever is needed, which reverses the twentieth-century approach.
What's still uncertain
- Asthma deaths continue to occur, and audits consistently find preventable factors in most of them.